Nigel Horscroft

1.5k total citations
23 papers, 1.0k citations indexed

About

Nigel Horscroft is a scholar working on Epidemiology, Immunology and Molecular Biology. According to data from OpenAlex, Nigel Horscroft has authored 23 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Epidemiology, 10 papers in Immunology and 8 papers in Molecular Biology. Recurrent topics in Nigel Horscroft's work include Hepatitis C virus research (7 papers), Immune Response and Inflammation (6 papers) and Influenza Virus Research Studies (5 papers). Nigel Horscroft is often cited by papers focused on Hepatitis C virus research (7 papers), Immune Response and Inflammation (6 papers) and Influenza Virus Research Studies (5 papers). Nigel Horscroft collaborates with scholars based in United States, United Kingdom and Germany. Nigel Horscroft's co-authors include W. Ian Lipkin, Mady Hornig, Herbert Weißenböck, Mariola Fotin‐Mleczek, Marylou V. Solbrig, Helen Bright, David C. Pryde, Edith Jasny, Heesik Yoon and Polly Roy and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Neuroscience and Journal of Virology.

In The Last Decade

Nigel Horscroft

23 papers receiving 970 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nigel Horscroft United States 16 334 320 306 239 123 23 1.0k
Etsuro Ono Japan 18 432 1.3× 287 0.9× 145 0.5× 134 0.6× 147 1.2× 87 997
Jessica M. Weidner United States 15 397 1.2× 253 0.8× 448 1.5× 366 1.5× 41 0.3× 16 1.2k
Andrea S. Bertke United States 18 463 1.4× 196 0.6× 164 0.5× 171 0.7× 100 0.8× 34 883
Hui Nie China 11 329 1.0× 307 1.0× 212 0.7× 101 0.4× 30 0.2× 29 915
Solomon O. Odemuyiwa United States 18 205 0.6× 193 0.6× 364 1.2× 108 0.5× 30 0.2× 47 1.1k
Brian M. Sullivan United States 18 424 1.3× 371 1.2× 954 3.1× 587 2.5× 135 1.1× 31 1.9k
Laure K. Case United States 19 166 0.5× 414 1.3× 455 1.5× 251 1.1× 239 1.9× 34 1.2k
Emily Wendt United Kingdom 9 127 0.4× 304 0.9× 286 0.9× 186 0.8× 262 2.1× 12 948
Limin Yang China 21 224 0.7× 441 1.4× 302 1.0× 273 1.1× 88 0.7× 79 1.2k
Ning Chai United States 16 452 1.4× 353 1.1× 171 0.6× 172 0.7× 194 1.6× 42 991

Countries citing papers authored by Nigel Horscroft

Since Specialization
Citations

This map shows the geographic impact of Nigel Horscroft's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nigel Horscroft with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nigel Horscroft more than expected).

Fields of papers citing papers by Nigel Horscroft

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nigel Horscroft. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nigel Horscroft. The network helps show where Nigel Horscroft may publish in the future.

Co-authorship network of co-authors of Nigel Horscroft

This figure shows the co-authorship network connecting the top 25 collaborators of Nigel Horscroft. A scholar is included among the top collaborators of Nigel Horscroft based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nigel Horscroft. Nigel Horscroft is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Thran, Moritz, et al.. (2023). Co-administration of an effector antibody enhances the half-life and therapeutic potential of RNA-encoded nanobodies. Scientific Reports. 13(1). 14632–14632. 6 indexed citations
2.
Cacicedo, Maximiliano L., Beate K. Straub, Jürgen G. Okun, et al.. (2022). mRNA-based therapy proves superior to the standard of care for treating hereditary tyrosinemia 1 in a mouse model. Molecular Therapy — Methods & Clinical Development. 26. 294–308. 11 indexed citations
3.
Cacicedo, Maximiliano L., Katja Hilbert, Nigel Horscroft, et al.. (2022). Phenylalanine hydroxylase mRNA rescues the phenylketonuria phenotype in mice. Frontiers in Bioengineering and Biotechnology. 10. 993298–993298. 22 indexed citations
4.
Pinheiro, Iris, Imma Raurell, Marcel A. de Leeuw, et al.. (2022). A Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo. Biomedicines. 10(5). 1191–1191. 6 indexed citations
5.
Hauser, Stefan, Stefanie Schuster, Jan-Åke Gustafsson, et al.. (2019). mRNA as a Novel Treatment Strategy for Hereditary Spastic Paraplegia Type 5. Molecular Therapy — Methods & Clinical Development. 15. 359–370. 24 indexed citations
6.
Thran, Moritz, Jean Mukherjee, Katja Fiedler, et al.. (2017). mRNA mediates passive vaccination against infectious agents, toxins, and tumors. EMBO Molecular Medicine. 9(10). 1434–1447. 131 indexed citations
7.
Edwards, Darin, Edith Jasny, Heesik Yoon, et al.. (2017). Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response. Journal of Translational Medicine. 15(1). 1–1. 141 indexed citations
8.
Colman, Peter, Frances Burden, Carl Laxton, et al.. (2012). Therapy with TLR7 Agonists Induces Lymphopenia: Correlating Pharmacology to Mechanism in a Mouse Model. Journal of Clinical Immunology. 32(5). 1082–1092. 20 indexed citations
9.
Horscroft, Nigel, David C. Pryde, & Helen Bright. (2012). Antiviral applications of Toll-like receptor agonists. Journal of Antimicrobial Chemotherapy. 67(4). 789–801. 52 indexed citations
10.
Flores, María Victoria, Timothy P. Hickling, Sasha Sreckovic, et al.. (2012). Preclinical Studies of Pf-04849285, An Interferon-α8 Fusion Protein for the Treatment of HCV. Antiviral Therapy. 17(5). 869–881. 4 indexed citations
11.
Fidock, Mark, Carl Laxton, Peter Colman, et al.. (2011). The Innate Immune Response, Clinical Outcomes, and Ex Vivo HCV Antiviral Efficacy of a TLR7 Agonist (PF-4878691). Clinical Pharmacology & Therapeutics. 89(6). 821–829. 64 indexed citations
12.
Murray, Edward J., Frances Burden, Nigel Horscroft, Caroline Smith‐Burchnell, & Mike Westby. (2011). Knockdown of USP18 Increases Alpha 2a Interferon Signaling and Induction of Interferon-Stimulating Genes but Does Not Increase Antiviral Activity in Huh7 Cells. Antimicrobial Agents and Chemotherapy. 55(9). 4311–4319. 12 indexed citations
13.
Clarke, Sarah L. N., et al.. (2008). Comparison of Rat and Human Responses to Toll-Like Receptor 7 Activation. Journal of Interferon & Cytokine Research. 29(2). 113–126. 3 indexed citations
14.
Laxton, Carl, et al.. (2007). Investigating Toll-Like Receptor Agonists for Potential To Treat Hepatitis C Virus Infection. Antimicrobial Agents and Chemotherapy. 51(8). 2969–2978. 50 indexed citations
15.
Horscroft, Nigel, Israr-ul H. Ansari, Vicky C. H. Lai, et al.. (2005). Establishment of a Subgenomic Replicon for Bovine Viral Diarrhea Virus in Huh-7 Cells and Modulation of Interferon-Regulated Factor 3-Mediated Antiviral Response. Journal of Virology. 79(5). 2788–2796. 31 indexed citations
16.
Horscroft, Nigel, et al.. (2005). Replicon Cell Culture System as a Valuable Tool in Antiviral Drug Discovery against Hepatitis C Virus. Antiviral chemistry & chemotherapy. 16(1). 1–12. 41 indexed citations
17.
Cheney, I. Wayne, Vicky C. H. Lai, Michelle Walker, et al.. (2002). Mutations in NS5B Polymerase of Hepatitis C Virus: Impacts on in Vitro Enzymatic Activity and Viral RNA Replication in the Subgenomic Replicon Cell Culture. Virology. 297(2). 298–306. 44 indexed citations
18.
Solbrig, Marylou V., Robert Schlaberg, Thomas Briese, Nigel Horscroft, & W. Ian Lipkin. (2002). Neuroprotection and Reduced Proliferation of Microglia in Ribavirin-Treated Bornavirus-Infected Rats. Antimicrobial Agents and Chemotherapy. 46(7). 2287–2291. 22 indexed citations
19.
Hornig, Mady, Marylou V. Solbrig, Nigel Horscroft, Herbert Weißenböck, & W. Ian Lipkin. (2001). Borna Disease Virus Infection of Adult and Neonatal Rats: Models for Neuropsychiatric Disease. Current topics in microbiology and immunology. 253. 157–177. 70 indexed citations
20.
Hornig, Mady, Herbert Weißenböck, Nigel Horscroft, & W. Ian Lipkin. (1999). An infection-based model of neurodevelopmental damage. Proceedings of the National Academy of Sciences. 96(21). 12102–12107. 215 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Etsuro Ono Breakdown of academic impact, for papers by Jessica M. Weidner Breakdown of academic impact, for papers by Andrea S. Bertke Breakdown of academic impact, for papers by Hui Nie Breakdown of academic impact, for papers by Solomon O. Odemuyiwa Breakdown of academic impact, for papers by Brian M. Sullivan Breakdown of academic impact, for papers by Laure K. Case Breakdown of academic impact, for papers by Emily Wendt Breakdown of academic impact, for papers by Limin Yang Breakdown of academic impact, for papers by Ning Chai
Rankless by CCL
2026